Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy (HCC)

CHA University

Status

Completed

Conditions

Hepatocellular Carcinoma

Treatments

Drug: atezolizumab plus bevacizumab

Study type

Observational

Funder types

Other

Identifiers

NCT05197504

2021-11-019

Details and patient eligibility

About

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide, and HCC is more frequently observed in Asia, including South Korea. As HCC is often accompanied by chronic hepatitis B or C virus and liver cirrhosis, treatment of HCC consider not only the tumor but also various factors such as liver function and the patient's performance status. Local treatment and surgery are possible in the early stages of HCC. However, it has a high recurrence rate even after curative surgeries due to underlying cirrhosis and the tumor microenvironment.

Although several studies have investigated gene mutations and differences in treatment response in advanced HCC through next-generation sequencing (NGS), studies on transcriptome analysis of advanced HCC through RNA-sequencing are hard to find, with a need for future research into precise classification and clinical significance of HCC based on multi-omics data.

Full description

to establish multi-omics data and discover biomarkers highly associated with treatment response in HCC patients

Enrollment

166 patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Those above the age of 20 who understand the purpose of the study and agree to participate in the collection of samples during the study.
Patients who have been diagnosed with unresectable advanced HCC through imaging, histological, or cytological tests.
Patients who underwent an NGS test with advanced HCC tissues
Patients who are scheduled to receive systemic treatment
Patients with measurable lesions based on RECIST v1.1
ECOG performance status 0 or 1
Patients with a life expectancy of at least three months

Exclusion criteria

Patients who have systemic conditions accompanied by instability of vital signs, such as infections or organ failure
Those with mental/neurological conditions or dementia who have difficulties understanding and completing the consent form
Those who are assessed as not suitable for this study, at the discretion of the researcher